Selective ezrin inhibitor NSC305787 is an experimental anti-cancer agent that has been so far evaluated only in pre-clinical studies which showed that NSC305787 has acceptable toxicity and pharmacokinetics profiles in murine models [12]. The gene discussed is EZR; the disease is cancer.